CSI Market
Sign In | Register

Integra Lifesciences Holdings (IART) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access IART quarterly Cash Flow →
Observing cash flow movements over recent quarters helps explain how Integra Lifesciences Holdings adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-516.47
Depreciation & amortization151.83
Amortization of Other Assets0.00
Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability490.04
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-46.76
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation18.58
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Non Cash Interest Expense Cash Flow-
Available For Sale Securities Gross Realized Gain Loss Net-
Amortization Of Debt Issuance Costs And Debt Refinanced Fees5.61
Noncash Or Part Noncash In Process Research And Development-
Increase Decrease In Contract With Customer Liability3.40
Income taxes-66.26
Gain (Loss) on Sale of Investments0.00
Increase (Decrease) in Accounts Receivable-0.49
Increase (Decrease) in Accounts Payable and Accrued Liabilities26.72
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.80
Other Working Capital-13.81
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.80
Discontinued operations0.00
Net Cash flow from Operating Activities50.38
Investing Activities
Capital Expenditures-95.64
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Short-term Investments7.00
Short-term Investments Acq.0.00
Payments for (Proceeds from) Derivative Instrument, Investing Activities-10.92
Proceeds from Working Capital Adjustment-
Proceeds from Payments For Business Acquisitions-
Payments To Acquire In Process Research And Development Milestone-
Payments For Proceeds From Business Acquisitions-
Payments To Acquire In Process Research And Development And Intangible Assets-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-8.50
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Proceeds from Collection of Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-108.06
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-4.06
Long-term debt - borrowings720.70
Long-term debt - repayments-669.89
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.74
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-19.15
Purchase Of Option Hedge On Convertible Notes-
Payments For Option Index To Issuers Equity-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities28.34
Effect of exchange rate on cash flow18.02
Discontinued operations0.00
Free Cash Flow-45.25
Total Cash Flow-11.33
4 historic quarters locked

Sign in to unlock the full Integra Lifesciences Holdings cash flow history.

Sign In Create Free Account

About Integra Lifesciences Holdings Corp Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: iart-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000917520-26-000011

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License